At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 24 enrolled
Drug / intervention
rhPTH(1-84) +2 moredrug
Likely dose
rhPTH(1-84) 25 mcgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1, Open-label, Randomized, Cross-over Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of a Single Dose of rhPTH(1-84) Administered Subcutaneously in Japanese Healthy Subjects Compared With Matched Non-Hispanic, Caucasian Healthy Adult Subjects and to Assess Dose Proportionality of 3 Doses of rhPTH(1-84) in the Japanese Subjects
In Brief
A Phase 1 clinical trial evaluating rhPTH(1-84) for Hypoparathyroidism. Completed, enrolled 24 participants across 1 site.
Detailed Summary
The purpose of this study is to compare how rhPTH(1-84) affects the body between healthy adults of Japanese descent and matched, healthy Caucasian adults.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypoparathyroidism
CountriesUnited States
Collaborators--
Timeline
Phase 1CompletedFinished
201820192020202120222023202420252026
First PostedMay 2017
Enrollment StartMay 2017
Primary CompletionJun 2017
TodayJul 2026
First PostedMay 12, 2017
Enrollment StartMay 16, 2017
Primary CompletionJun 26, 2017
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 9.1 years ago
Interventions
rhPTH(1-84)drug
25 mcg rhPTH(1-84) SC injection
rhPTH(1-84)drug
50 mcg rhPTH(1-84) SC injection
rhPTH(1-84)drug
100 mcg rhPTH(1-84) SC injection